4 chapters across the catalog
Wegovy Pediatric Promotion, Pharmaceutical Native Advertising
PBS aired a segment promoting the use of weight-loss drugs like Wegovy for children as young as 12, citing a 600% increase in usage. The hosts criticize the report as "native advertising," arguing that the medical establishment is using chemicals to treat symptoms of a toxic food supply rather than addressing dietary causes.
New data from the CDC indicates a 2.5% increase in ADHD diagnoses among children aged 5 to 17 since 2019, totaling nearly 6 million children. Medical commentators on Good Morning America suggested the rise is due to decreased stigma and better awareness rather than an actual increase in the condition. However, skeptics point to the role of pharmaceutical marketing in driving parents to seek diagnoses that lead to long-term medication.
The FDA approved the use of Oxycontin for children as young as 11 years old, sparking concerns about addiction risks in minors. While some doctors argue the narcotic is necessary for children battling terminal cancer, critics point to the high volume of opioid prescriptions in the U.S. as evidence of over-medication.
Pediatric Anti-Psychotic Medication Trends, Ritalin Overuse
The rate of children aged two to five receiving anti-psychotic medications has reportedly doubled in recent years. The discussion criticizes the medicalization of normal childhood behavior, such as excitability, which was previously managed without pharmaceutical intervention. Personal anecdotes suggest that early exposure to drugs like Ritalin can lead to long-term addiction issues and social instability.
